Table 3:

Hazard ratios (HR) for Overall Survival (OS) and Progression-free survival (PFS) for specific subsets

Variable	OS		PFS
	HR	95%CI	HR	95%CI
Sex (Female vs Male)	1.76	0.68–4.50	1.29	0.70–2.36
Smoking History (No vs Yes)	0.70	0.27–1.78	0.94	0.57–1.55
Upper vs Lower tract	1.19	0.33–4.29	1.32	0.64–2.74
Histology (pure vs mixed UC)	1.09	0.37–3.21	0.91	0.52–1.57
PBC Regimen (Cis vs Carbo)	2.25	0.88–5.77	1.58	0.90–2.76
Cycles of PBC (≤4 vs >4)	0.80	0.30–2.15	1.13	0.67–1.91
Liver mets at start of PBC (Yes vs No)*	1.06	0.35–3.18	2.32	1.17–4.59
ECOG PS (0 vs ≥1) at start of PBC*	0.15	0.05–0.47	0.64	0.38–1.06
Best response to PBC (CR/PR vs SD)*	0.33	0.13–0.87	0.61	0.34–1.08
Weeks from PBC end to avelumab initiation (≤3 vs 4–10)	1.46	0.48–4.41	1.59	0.84–3.00
Weeks from PBC end to avelumab initiation (>10 vs 4–10)	0.59	0.13–2.75	0.44	0.19–1.05

CI: Confidence Interval, CR: Complete Response, ECOG PS: Eastern Cooperative Oncology Group Performance Status, Mets: Metastases, OS: Overall Survival, HR: Hazard Ratio, PBC: Platinum-based Chemotherapy, PFS: Progression-Free Survival, PR: Partial Response, SD: Stable disease

^*Significant variables (a = 0.05)